Arcus Biosciences Inc represents a strong commitment to revolutionizing the treatment of cancer through innovative research and development. With a focus on developing next-generation immune-oncology therapies, the company aims to harness the power of the immune system to eradicate cancer cells. Arcus Biosciences Inc embraces a collaborative and patient-centric approach, working closely with partners and healthcare providers to improve outcomes for cancer patients worldwide. The company's mission is to deliver transformative medicines and bring hope to individuals facing this devastating disease.

Arcus Biosciences Inc primarily operates in the United States.

Arcus Biosciences Inc has achieved several significant milestones. In April 2021, Arcus announced positive Phase 3 trial results for its investigational cancer immunotherapy, zimberelimab. The drug showed promising efficacy and safety profile in treating patients with metastatic non-small cell lung cancer. Additionally, in February 2021, Arcus entered into a collaboration and license agreement with AstraZeneca, enabling the development and commercialization of zimberelimab in combination with AstraZeneca's Imfinzi for multiple cancer types. These milestones demonstrate Arcus Biosciences Inc's dedication to advancing innovative treatments for cancer patients and forging strategic partnerships to expand its therapeutic reach.

Arcus Biosciences Inc is a renowned biotech company specializing in developing innovative cancer therapies. Founded in 2015, Arcus Biosciences has rapidly become a leader in the field, leveraging its deep scientific expertise and cutting-edge technology. The company is dedicated to advancing the understanding of the immune system's role in combating cancer and harnessing this knowledge to create transformative treatments. Arcus Biosciences has established strategic collaborations with leading pharmaceutical companies to facilitate the development and commercialization of its therapies. With its robust pipeline and commitment to improving patient outcomes, Arcus Biosciences Inc is poised to make significant contributions in the fight against cancer.

The main competitors of Arcus Biosciences Inc in the market are other companies in the biotechnology and pharmaceutical industry. Some notable competitors include Bristol-Myers Squibb, Merck & Co., Inc., and AstraZeneca. These companies also focus on the development and commercialization of innovative therapies and drugs, similar to Arcus Biosciences Inc. However, Arcus Biosciences Inc distinguishes itself through its unique suite of next-generation cancer immunotherapies, leveraging its expertise in tumor immunology and targeting various immune checkpoints. With its cutting-edge research and strategic collaborations, Arcus Biosciences Inc aims to establish a strong presence and provide effective treatments in the highly competitive market.

Arcus Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Arcus Biosciences Inc focuses on developing and commercializing novel immunotherapies for treating cancer. By leveraging its expertise in cancer immunotherapy, the company aims to discover and develop innovative therapies that can modulate the immune system to fight against cancer cells. Arcus Biosciences Inc aims to bring transformative immunotherapies to patients by harnessing multiple complementary approaches, including antibody-based therapeutics, small molecules, and next-generation tumor-infiltrating lymphocyte cell therapy. With a strong commitment to advancing the field of oncology, Arcus Biosciences Inc continues to explore and develop potential treatments to improve patient outcomes and enhance survival rates in various types of cancer.

P/E odnos Arcus Biosciences iznosi -1,62.

KUV kompanije Arcus Biosciences iznosi 4,84.

AlleAktien kvalitativni skor za Arcus Biosciences je 1/10.

očekivana Arcus Biosciences promet je 151,57 mil. USD.

Dobit očekivana Arcus Biosciences je -452,45 mil. USD.

Arcus Biosciences Inc is a biopharmaceutical company based in Hayward, California, USA. The company focuses on the development of targeted immuno-oncology therapies that represent a new generation of cancer drugs. The business model of Arcus Biosciences consists of three main divisions, which include research, development, and marketing of cancer drugs. In research, Arcus Biosciences works closely with leading scientific institutions worldwide to gain new insights and highly effective technologies for the development of new cancer drugs. The company invests significant amounts in the research and development of new cancer therapies. The development phase of Arcus Biosciences involves extensive clinical research testing the efficacy and safety of new cancer drugs. The company collaborates with renowned partners and institutions to conduct high-quality clinical trials. Being specialized in targeted immuno-oncology therapies, the company has a wide range of products focused on immuno-oncology. The products range from small molecules to large biologics and are used for the treatment of various types of cancer. One example of a product from Arcus Biosciences is AB928, a small molecule that enhances the effect of T cells and other immune cells in the body. It is part of a new drug combination approach where multiple immuno-oncology drugs are used together to increase both the potential and effectiveness against various types of cancer. Another product from Arcus Biosciences is AB154, a monoclonal antibody that enhances the T-cell response against tumors by blocking a protein called TIGIT. It is currently being investigated in clinical trials for the treatment of various types of cancer. In addition to these products, the company has other immuno-oncology compounds in pipeline development, which are in late-stage clinical development. These include AB680 (an inhibitor of CDC7 kinase), AB122 (an antibody against PD-1), and AB308 (an antibody against TIGIT). The goal of Arcus Biosciences is to treat cancer patients with highly effective immunotherapies and thereby improve their chances of survival. With close collaboration with leading scientific institutions, conducting clinical trials, and an extensive product portfolio focused on immuno-oncology, the company is well-positioned to achieve its ambitions.

Arcus Biosciences isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Arcus Biosciences trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Arcus Biosciences je US03969F1093.

WKN od Arcus Biosciences je A2JGDZ.

Oznaka za praćenje akcija kompanije Arcus Biosciences je RCUS.

U poslednjih 12 meseci, Arcus Biosciences je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Arcus Biosciences će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Arcus Biosciences trenutno iznosi .

Arcus Biosciences isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Arcus Biosciences je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Arcus Biosciences se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Arcus Biosciences od 28. 4. 2025. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 28. 4. 2025..

Isplata poslednje dividende izvršena je 28. 4. 2025..

U godini 2024 kompanija Arcus Biosciences je isplatila 0 USD kao dividende.

Dividende od Arcus Biosciences se isplaćuju u USD.